Pulse Biosciences(PLSE)

Search documents
Pulse Biosciences(PLSE) - 2022 Q3 - Earnings Call Transcript
2022-11-11 01:02
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor – Investor Relations, Gilmartin Group Kevin Danahy – President and Chief Executive Officer Darrin Uecker – Chief Technology Officer Sandy Gardiner – Executive Vice President and Chief Financial Officer Conference Call Participants Operator Greetings and welcome to Pulse Biosciences Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-on ...
Pulse Biosciences(PLSE) - 2022 Q3 - Quarterly Report
2022-11-10 21:28
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bio ...
Pulse Biosciences(PLSE) - 2022 Q2 - Earnings Call Transcript
2022-08-10 23:40
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Darrin Uecker - President and Chief Executive Officer Kevin Danahy - Chief Commercial Officer Sandra Gardiner - Executive Vice President and Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group LLC Swayampakula Ramakanth - H.C. Wainwright & Co, LLC Operator Greetings, and welcome to Pulse Biosciences Second Qu ...
Pulse Biosciences(PLSE) - 2022 Q2 - Quarterly Report
2022-08-10 20:29
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscien ...
Pulse Biosciences(PLSE) - 2022 Q1 - Earnings Call Transcript
2022-05-12 01:42
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer Sandra Gardiner - Chief Financial Officer Kevin Danahy - Chief Commercial Officer Conference Call Participants Christopher Cooley - Stephens Swayampakula Ramakanth - H.C. Wainwright Jeremy Pearlman - Maxim Group Operator Greetings, and welcome to Pulse Biosciences First Quarter 2022 Earnings Conference Call. ...
Pulse Biosciences(PLSE) - 2022 Q1 - Quarterly Report
2022-05-11 20:32
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscie ...
Pulse Biosciences(PLSE) - 2021 Q4 - Earnings Call Transcript
2022-04-01 02:27
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2021 Earnings Conference Call March 31, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Anthony Vendetti - Maxim Group Operator Good afternoon and welcome to the Pulse Biosciences' Fourth Quarter and Full ...
Pulse Biosciences(PLSE) - 2021 Q4 - Annual Report
2022-03-31 20:56
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Form 10-K ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 _____________________________________ ...
Pulse Biosciences(PLSE) - 2021 Q3 - Earnings Call Transcript
2021-11-16 03:13
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2021 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Executive Vice President & Chief Financial Officer Conference Call Participants RK - H.C. Wainwright Chris Cooley - Stephens Anthony Vendetti - Maxim Group Operator Greetings and welcome to Pulse Biosciences' Third Qua ...
Pulse Biosciences(PLSE) - 2021 Q3 - Quarterly Report
2021-11-15 21:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bio ...